Pharmaceutical

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Jul 1, 2023 - 20:00
[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Read the original article

Tags:

Previous Article

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

Next Article

KP-910 by Kaken Pharmaceutical for Peripheral Neuropathic Pain: Likelihood of Ap...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK’s NICE recommends AstraZeneca’s olaparib to treat cancer types

UK’s NICE recommends AstraZeneca’s olaparib to treat ca...

Apr 8, 2023

Purdue receives clearance for opioid overdose injector for younger individuals

Purdue receives clearance for opioid overdose injector ...

Aug 9, 2024

EC grants approval to Pfizer for $43bn Seagen acquisition 

EC grants approval to Pfizer for $43bn Seagen acquisition 

Oct 21, 2023